Identification and Antigenicity of Broadly Cross-Reactive and Conserved Human Immunodeficiency Virus Type 1-Derived Helper T-Lymphocyte Epitopes

ABSTRACT Human immunodeficiency virus (HIV)-specific helper T lymphocytes (HTL) play a key role in the immune control of HIV type 1 (HIV-1) infection, and as such are an important target of potential HIV-1 vaccines. In order to identify HTL epitopes in HIV-1 that might serve as vaccine targets, conserved HIV-1-derived peptides bearing an HLA-DR binding supermotif were tested for binding to a panel of the most representative HLA-DR molecules. Eleven highly cross-reactive binding peptides were identified: three in Gag and eight in Pol. Lymphoproliferative responses to this panel of peptides, as well as to the HIV-1 p24 and p66 proteins, were evaluated with a cohort of 31 HIV-1-infected patients. All 11 peptides were recognized by peripheral blood mononuclear cells from multiple HIV-infected donors. Many of the responsive HIV-infected subjects showed recognition of multiple peptides, indicating that HIV-1-specific T-helper responses may be broadly directed in certain individuals. A strong association existed between recognition of the parental recombinant HIV-1 protein and the corresponding HTL peptides, suggesting that these peptides represent epitopes that are processed and presented during the course of HIV-1 infection. Lastly, responses to the supermotif peptides were mediated by CD4+ T cells and were restricted by major histocompatibility complex class II molecules. The epitopes described herein are potentially important components of HIV-1 therapeutic and prophylactic vaccines.

[1]  C. Pitcher,et al.  HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression , 1999, Nature Medicine.

[2]  J. Berzofsky,et al.  Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. , 1992, The Journal of infectious diseases.

[3]  N. Nagelkerke,et al.  Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya , 1996, The Lancet.

[4]  J. Berzofsky,et al.  HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. , 1994, JAMA.

[5]  J. Claverie,et al.  Identification of a major human immunodeficiency virus‐1 reverse transcriptase epitope recognized by mouse CD4+ T lymphocytes , 1991, European journal of immunology.

[6]  A. Vitiello,et al.  The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. , 1994, Journal of immunology.

[7]  J. Strominger,et al.  Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line. , 1987, The Journal of biological chemistry.

[8]  L. Kappos,et al.  Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. , 1993, The Journal of clinical investigation.

[9]  A. Lazzarin,et al.  Antigen-driven C–C Chemokine-mediated HIV-1 Suppression by CD4+ T Cells from Exposed Uninfected Individuals Expressing the Wild-type CCR-5 Allele , 1997, The Journal of experimental medicine.

[10]  S. Rowland-Jones,et al.  HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant , 1993, The Lancet.

[11]  J. Berzofsky,et al.  Human immunodeficiency virus reverse transcriptase T helper epitopes identified in mice and humans: correlation with a cytotoxic T cell epitope. , 1991, The Journal of infectious diseases.

[12]  M. Lederman,et al.  Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. , 1998, The Journal of infectious diseases.

[13]  S. Rowland-Jones,et al.  HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women , 1995, Nature Medicine.

[14]  Felipe García,et al.  Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease , 1998, The Lancet.

[15]  J. Berzofsky,et al.  Cellular immune factors associated with mother‐to-infant transmission of HIV , 1993, AIDS.

[16]  R. Arlinghaus,et al.  Identification of T-cell epitopes without B-cell activity in the first and second conserved regions of the HIV Env protein. , 1991, AIDS.

[17]  C. DeLisi,et al.  T cell multideterminant regions in the human immunodeficiency virus envelope: toward overcoming the problem of major histocompatibility complex restriction. , 1989, International immunology.

[18]  A. Mazzone,et al.  HIV‐specific lymphoproliferative responses in asymptomatic HIV‐infected individuals , 1995, Clinical and experimental immunology.

[19]  S. Rowland-Jones,et al.  Immune responses in HIV-exposed seronegatives: have they repelled the virus? , 1995, Current opinion in immunology.

[20]  D. Venzon,et al.  Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. , 1993, The Journal of clinical investigation.

[21]  J. Sidney,et al.  Effect of pH on MHC class II-peptide interactions. , 1992, Journal of immunology.

[22]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[23]  R. Kurth,et al.  Impaired specific cellular response to HTLV-III before other immune defects in patients with HTLV-III infection. , 1986, The New England journal of medicine.

[24]  J. Berzofsky,et al.  ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. , 1995, The Journal of clinical investigation.

[25]  W H Woolley,et al.  Theoretical biology and biophysics , 1971 .

[26]  D. Nixon,et al.  Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. , 2000, The Journal of infectious diseases.

[27]  D. Richman,et al.  T cell recognition of HIV synthetic peptides in a natural infection. , 1989, Journal of immunology.

[28]  M. Clerici,et al.  Protective immunity against HIV infection: has nature done the experiment for us? , 1996, Immunology today.

[29]  C Oseroff,et al.  Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. , 1994, Immunity.

[30]  J. Rothbard,et al.  Role of the polymorphic residues in HLA-DR molecules in allele-specific binding of peptide ligands. , 1994, Journal of immunology.

[31]  M. Clerici,et al.  HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals , 1997, Nature Medicine.

[32]  C Oseroff,et al.  On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs. , 1991, Journal of immunology.

[33]  G. Stewart,et al.  T-cell response to HIV in natural infection: optimized culture conditions for detecting responses to gag peptides. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[34]  Xiping Wei,et al.  Antiviral pressure exerted by HIV-l-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus , 1997, Nature Medicine.

[35]  J. Mellors,et al.  Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. , 1999, The Journal of infectious diseases.

[36]  C. DeLisi,et al.  Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Clerici,et al.  Early T-helper cell defects in HIV infection. , 1991, AIDS.

[38]  J. Sidney,et al.  Strong similarities in antigen fine specificity among DRB1* 1302-restricted tetanus toxin tt830-843-specific TCRs in spite of highly heterogeneous CDR3. , 1995, Journal of immunology.

[39]  J. Sidney,et al.  HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. , 1998, Current opinion in immunology.

[40]  A. Landay,et al.  Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease , 2000, AIDS.

[41]  M F del Guercio,et al.  Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.

[42]  J Leibowitch,et al.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. , 1997, Science.

[43]  S. H. van der Burg,et al.  Identification of a conserved universal Th epitope in HIV-1 reverse transcriptase that is processed and presented to HIV-specific CD4+ T cells by at least four unrelated HLA-DR molecules. , 1999, Journal of immunology.

[44]  H. Grey,et al.  Structural analysis of peptides capable of binding to more than one Ia antigen. , 1989, Journal of immunology.

[45]  J. Berzofsky,et al.  Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types. , 1991, The Journal of clinical investigation.

[46]  E. Chartash,et al.  Human immunodeficiency virus infection of helper T cell clones. Early proliferative defects despite intact antigen-specific recognition and interleukin 4 secretion. , 1989, The Journal of clinical investigation.

[47]  Spyros A. Kalams,et al.  The Critical Need for CD4 Help in Maintaining Effective Cytotoxic T Lymphocyte Responses , 1998, The Journal of experimental medicine.

[48]  B. Walker,et al.  Lack of Viral Escape and Defective In Vivo Activation of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes in Rapidly Progressive Infection , 1999, Journal of Virology.

[49]  E. Rosenberg,et al.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. , 1997, Science.